As of March 24, 2020, there were 315 pivotal trials of unapproved, novel drugs that are approaching readout during 2020. These studies are at risk of being compromised due to the coronavirus (Covid-19) pandemic, costing pharmaceutical companies both time and money. There were 147 active trials at risk, with an estimated cost of nearly 12 billion U.S. dollars.
Pivotal studies of novel drugs at risk due to COVID-19 pandemic as of March 24, 2020*
Characteristic
Trial count
Total enrolment
Estimated total cost of running these studies (in billion U.S. dollars)
* Vantage searched specifically for pivotal-stage projects that have yet to receive US approval, in trials that have a 2020 primary completion date, according to clinicaltrials.gov.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
Vantage. (March 24, 2020). Pivotal studies of novel drugs at risk due to COVID-19 pandemic as of March 24, 2020* [Graph]. In Statista. Retrieved November 10, 2024, from https://www.statista.com/statistics/1106662/pivotal-trials-on-novel-drugs-at-risk-doe-to-coronavirus-by-stage/
Vantage. "Pivotal studies of novel drugs at risk due to COVID-19 pandemic as of March 24, 2020*." Chart. March 24, 2020. Statista. Accessed November 10, 2024. https://www.statista.com/statistics/1106662/pivotal-trials-on-novel-drugs-at-risk-doe-to-coronavirus-by-stage/
Vantage. (2020). Pivotal studies of novel drugs at risk due to COVID-19 pandemic as of March 24, 2020*. Statista. Statista Inc.. Accessed: November 10, 2024. https://www.statista.com/statistics/1106662/pivotal-trials-on-novel-drugs-at-risk-doe-to-coronavirus-by-stage/
Vantage. "Pivotal Studies of Novel Drugs at Risk Due to Covid-19 Pandemic as of March 24, 2020*." Statista, Statista Inc., 24 Mar 2020, https://www.statista.com/statistics/1106662/pivotal-trials-on-novel-drugs-at-risk-doe-to-coronavirus-by-stage/
Vantage, Pivotal studies of novel drugs at risk due to COVID-19 pandemic as of March 24, 2020* Statista, https://www.statista.com/statistics/1106662/pivotal-trials-on-novel-drugs-at-risk-doe-to-coronavirus-by-stage/ (last visited November 10, 2024)
Pivotal studies of novel drugs at risk due to COVID-19 pandemic as of March 24, 2020* [Graph], Vantage, March 24, 2020. [Online]. Available: https://www.statista.com/statistics/1106662/pivotal-trials-on-novel-drugs-at-risk-doe-to-coronavirus-by-stage/
